This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader impli…
If a federal advisory panel gets its way, health insurers will soon have greater incentives to manage beneficiaries’ prescription drug use and negotiate discounts with pharmaceutical manufacturers, the New York Times reports.
The Medicare Payment Advisory Commission’s annual report offers five payment recommendations including reforms for two post-acute care providers, a 10 percent cut to drug payments for safety-net hospitals and changes to Medicare Advantage diagnosis coding.
A recently released list of financial penalties imposed on Medicare Part C and Part D plan sponsors shows that the government is increasingly coming down hard on health plans that violate federal regulations.
Federal regulators have banned Cigna from selling new Medicare products because of issues with its Part C and Part D plans that increased enrollees’ out-of-pocket expenses which led to delays or denials in receiving medical services and prescription drugs.
As one of the youngest government-run health programs, Medicare Part D has been around for less than a decade, meaning it’s just reaching the beginning stages of adolescence. And, like most…